Skip to content

Critical Care Anxiety and Long-Term Outcomes Management

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02421861
Acronym
CALM
Enrollment
10
Registered
2015-04-21
Start date
2015-04-30
Completion date
Unknown
Last updated
2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety

Keywords

anxiety, intensive care unit, critical care

Brief summary

The aims of this study are to (1) test the benefits of a non-pharmacologic anxiety management approach with patients who are critically ill and/or traumatically injured during intensive care hospitalization and (2) test whether this approach reduces anxiety and improves engagement in rehabilitation therapies, shortens duration of hospitalization, and improves psychological and quality of life outcomes.

Interventions

BEHAVIORALAnxiety Management in the ICU

The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference.

OTHERUsual Care (UC)

The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.

Sponsors

University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Ability to read, write, and speak English * Alert (Best RASS ICU sedation score ≥-2) * Current CAM-ICU test negative * Expected ICU stay ≥48 hours * Anxiety Visual Analog Scale (VAS-A) score ≥30 * Prescribed rehabilitation therapy at eligibility

Exclusion criteria

* Inability to communicate (verbally, or via hand writing/gestures) * Greater than 90% probability of mortality in hospital * Anticipated discharge to hospice or transition to end-of-life care * Pre-existing cognitive impairment (e.g., dementia, pervasive developmental disorder)

Design outcomes

Primary

MeasureTime frameDescription
Anxiety (Visual Analog Scale for Anxiety (VAS-A)Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 daysAnxiety at discharge and change in anxiety from baseline to discharge as measured by the Visual Analog Scale for Anxiety (VAS-A)

Secondary

MeasureTime frame
Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days)
Length of ICU and Hospital StayMeasured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days)
Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS)
Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)3 months after enrollment as measured by the PCL-5
Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36)3 months after enrollment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026